ExThera Medical: Will Its Seraph™ Device Eliminate Bacteremia and Prevent Sepsis at Point-of-Care?

The first start-up by Bob Ward—The Polymer Technology Group (PTG)—earned a 555X return for investors upon its sale in 2008 to DSM, the global life sciences and materials company. Now, Bob Ward’s swinging away at another potential homerun: ExThera Medical, a Berkeley, California-based company, with its scientific origins at the Karolinska Institute in Stockholm, Sweden.

Read more »

Bulls, Bears: Sepsis and Anti-Infectives in the Public Markets

The threat of infection in hospital and other treatment facilities have dramatically increased over the last few years. Antibiotics and other therapies have become impotent against certain pathogens and infections, increasing the need for research funding for creating new antibiotics. These three companies have the potential to solve a significant unmet medical need.

Read more »

A Potential New Treatment for Sepsis

An international research team recently reported a breakthrough in the treatment of a life-threatening condition that affects approximately 20 million people per year.

Read more »

In Septic Shock: Are We in the Early Stages of a Sepsis Epidemic?

Few people outside the medical profession have even heard of Sepsis, the third most common cause of death for hospitalized […]

Read more »